Quick Answer
Apimeds Pharmaceuticals US, Inc. reported Research And Development Expense of $98.5 thousand for the year ending 2023.
- This data is from Apimeds Pharmaceuticals US, Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2023 to 2023 (1 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2025: $651.8 thousand | Q3 2025: $619.7 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: